author-photo

Andrew McMillan

Nottingham University Hospitals NHS Trust
University of Nottingham
Nottingham City Hospital

143

Papers

5232

Citations

Citation Trend

Filter By

Papers (101) Sort By

Journal Conference Others

First Analysis of the UKALL14 Randomized Trial to Determine Whether the Addition of Nelarabine to Standard Chemotherapy Improves Event Free Survival in Adults with T-Cell Acute Lymphoblastic Leukaemia (CRUK/09/006)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Pathfinder: A gamified measure to integrate general cognitive ability into the biological, medical and behavioural sciences

2021 bioRxiv
Show All
- Source
- Cite
- Save
Citations (1)
A trust framework for digital food systems

2021
Show All
- Source
- Cite
- Save
Citations (0)
Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.

2021 Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
OUTCOME OF LARGE B-CELL LYMPHOMA PATIENTS FAILING CD19 TARGETED CAR-T THERAPY

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Genetic and genomic analysis of acute lymphoblastic leukaemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials.

2021 Haematologica
Show All
- Source
- Cite
- Save
Citations (0)
MODIFICATION OF ESCALATED BEACOPP WITH DACARBAZINE SUBSTITUTION REDUCES TOXICITY WHILE MAINTAINING EFFICACY FOR THE TREATMENT OF ADVANCED STAGE HODGKIN LYMPHOMA

2021 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)
The Consequences of the COVID-19 Crisis for the Mental Health of Young Adult Twins in England and Wales

2021 Behavior Genetics
Show All
- Source
- Cite
- Save
Citations (0)
Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.

2021 The Lancet Haematology
Show All
- Source
- Cite
- Save
Citations (1)
Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)